Table 1. Characteristics of studies included in Meta-Analysis.
| Source | study design | NO. | age, y | Sex (male) | NIHSS ( median) | Intervention | Time window (mean) | follow-up | Jadad score | Allocation concealment |
|---|---|---|---|---|---|---|---|---|---|---|
| Broderick 2013 | RCT | 656 | 18-82 | 340(51.83%) | ET 17,IVT 16 | ET after IV t-PA versus IV t-PA | ET 5 h,IVT 3 h | 90 days | 5 | Yes |
| Ciccone 2013 | RCT | 362 | 18-80 | 209(57.73%) | ET 13,IVT 13 | ET versus IV t-PA | ET 3.75 h,IVT 2.75 h | 90 days | 5 | Yes |
| Ciccone 2010 | RCT | 54 | 18-80 | 42(77.78%) | IAT 17,IVT 16 | IA alteplase versus IV alteplase | IAT3.15 h,IVT 2.35 h | 90 days | 5 | Yes |
| Sen 2009 | RCT | 7 | 68±16 | 5(71.43%) | 16 | IAt-PA versus IV t-PA | within 3 h | 90 days | 4* | Inadequate |
| Ducrocq 2005 | RCT | 27 | 18-79 | 21(77.78%) | Mean SSS:IAT 20.8,IVT 19.6 | IA urokinase versus IV urokinase | IAT: 5.24h, IVT: 4.16h | 90 days | 4* | Yes |
*
Randomization method was not described.
NIHSS, National Institutes of Health Stroke Scale; RCT, Randomized Controlled Trial; ET, Endovascular Treatment; IAT, intra-arterial thrombolysis; IVT, intravenous thrombolysis; IA, intra-arterial; IV, intravenous; SSS, Scandinavian Stroke Scale; MCA, middle cerebral artery; NG, not give; h, hour; ITT, intention-to-treat.